

## DAFTAR PUSTAKA

1. Belperio PS, Rhew DC. Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of literature. *Am J med.* 2004; 116 (Suppl 7A) : S27 – 43
2. Shen Y, Wang Z, Lu H, Wang J, Chen J, Liu L *et al.* Prevalence of anemia among adults with newly diagnosed HIV/AIDS in China. *PLoS ONE* 2013. 8(9): e73807
3. Jam S, Ramezani A, Sabzvari D, Badie BM, Alinaghi SA, Jabbari H *et al.* A Cross-Sectional of Anemia in Human Immunodeficiency Virus-Infected Patients in Iran. *Arch Iranian Med* 2009;12(2): 145 – 150
4. Obirikorang C, Issahaku RG, Osakunor DNM, Yeboah JO. Anemia and iron hemostasis in a cohort of HIV – related patients: a cross- sectional study in Ghana. *AIDS Research and Treatment* Volume 2016: 1 – 8
5. Gebremedhin KB, Haye TB. Factor Associated with anemia among people living with HIV/AIDS taking ART in Ethiopia. *Advances in Hematology* Volume 2019: 1 – 8
6. Wicaksana R, Sumantri R, Indrati AR, Zwitter A, Jusuf H, Mast Q *et al.* Anemia and iron homeostasis in Cohort of HIV-infected patients in Indonesia. *BMC Infectious Diseases.* 2011,11:213
7. Sumantri R, Wicaksana R, Ariantana AR. Prevalensi dan faktor risiko anemia pada HIV-AIDS. *MKB.*2009, 41 (4):187 – 93
8. Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. *Cold Spring Harb Perspect Med.* 2011,1: 1 – 22
9. World Health Organization. Global Health Observatory (GHO) Data, 2014
10. UNAIDS. UNAIDS Report 2013 : HIV in Asia and the Pacific, 2014
11. Kementerian Kesehatan RI. Laporan perkembangan HIV AIDS & infeksi menular seksual (IMS) triwulan I tahun 2021. 2021. Jakarta : Kementerian Kesehatan
12. Salome MA, Grotto HZ. Human immunodeficiency virus – related anemia of chronic disease: relationship to hematologic, immune, and iron metabolism parameters, and lack of association with serum interferon- $\gamma$

- levels. *AIDS Patient Care and STD*. Volume 16, Number 8, 2002: 361 – 365
13. Mata-Marin JA, Gaytan-Martinez JE, Martinez-Martinez RE, Arroyo-Anduiza CI, Fuentes-Allen JL, Casarrubias-Ramirez M. Risk factors and correlates for anemia in HIV treatment-naïve infected patients: a cross-sectional analytical study. *BMC Research Notes*. 2010,3:230
  14. Volberding PA, Levine AM, Dieterich D, Mildvan D, Mitsuyasu R, Saag M. Anemia in HIV infection: clinical impact and evidence-based management strategies. *Clinical Infectious Disease*. 2004; 38: 1454 – 63
  15. Redig AJ, Berliner N. Pathogenesis and clinical implication of HIV-related anemia in 2013. *Hemathology*. 2013, 2013:377 – 81
  16. Kreuzer KA, Rockstroh JK. Pathogenesis and pathophysiology of anemia in HIV infection. *Ann Hematol*. 1997, 75:179 – 187
  17. Camacho J, Poveda F, Zamorano AF, Valencia ME, Vazquez JJ, Arnalich F. Serum erythropoietin levels in anemic patients with advanced human immunodeficiency virus infection. *British Journal of Haematology*. 1992,82: 608 – 614
  18. Grotto HZW, Salome MA. Human immunodeficiency virus-related anemia of chronic disease: relationship to hematologic, immune, and iron metabolism parameters, and lack of association with serum interferon  $\gamma$  levels. *AIDS Patients Care and STDs* volume 16. 2002,8 : 361 – 5
  19. Kreuzer KA, Rockstroh JK, Jelkman W, Theisen A, Spengler U, Saurbruch T. Inadequate erythropoietin response to anemia in HIV patients: relationship to serum levels of tumour necrosis factor – alpha, interleukin – 6 and their soluble receptors. *British Journal of Haematology*. 1997, 96.235 – 239
  20. Olu-Taiwo A, Amusu AO, Olatunya OS, Adediran A, Ajayi EA, Ogbenna AA *et al*. Impaired appropriateness of erythropoietin in anemic HIV infected patients. *International Blood Research & Reviews*. 2016; 6 (1): 1 – 8
  21. Hasbie NF, Detty AU, Syuhada, Mediana M. Korelasi kadar CD4 dengan kadar hemoglobin sebelum terapi ARV pada penderita HIV / AIDS di

RSUD DR. H. Abdul Moeloek. Jurnal Ilmu Kedokteran dan Kesehatan vol 6. 2019; 3: 176 – 185

22. D'andrea G, Brisdelli F, Bozzi A. AZT: An old drug with new perspectives. *Current Clinical Pharmacology*. 2008 : 3: 1 – 18
23. Scarsi KK, Eisen G, Darin KM, Meloni ST, Rawizza HE, Tchetgen EJ *et al*. Superior effectiveness of zidovudine compare with tenofovir when combined with nevirapine-based antiretroviral therapy in a large Nigerian cohort. *Clinical Infectiois Diseases*. 2015; 1 – 7
24. Hodges VM, Rainey S, Lappin TR, Maxwell. Pathophysiology of anemia and erythrocytosis. *Critical Reviews in Oncology/Hematology*, 64 (2007): 139 – 158
25. Nijhof W, Wierenga PK, Sahr K, Beru N, Goldwasser E. Induction of globin mRNA transcription by erythropoietin in differentiating erythroid precursor cells. *Exp Hematol* 1987; 15: 779 – 83.
26. Mufson RA, Gesner TG. Binding internalization of recombinant human erythropoietin in murine erythroid precursor cells. *Blood* 1987; 69: 1485 – 90.
27. Mason-Garcia M, Weill CL, Beckman BS. Rapid activation by erythropoietin of protein kinase C in nuclei of erythroid progenitor cells. *Biochem Biophys Res Commun* 1990; 168: 490 – 7.
28. Bissonnette RP, Rungta D, Hudson AR, Roach SL, Hong MH, Sun H *et al*. Non-Peptidyl small molecule EPO receptor agonists are potent pathway selective inducers of erythropoiesis. *Blood*. 2010 ;116 (21) : 1565
29. Bakta IM. *Hematologi Klinik Ringkas*. Jakarta: EGC, 2006
30. Durandt C, Khoosal R, Herd CL, Pepper MS. HIV and haematopoesis. *S afr Med J*. 2019; 109 (8 suppl 1): S41 – S46
31. Minchella PA, Armitage AE, Darboe B, Jallow MW, Drakesmith H, Jaye A *et al*. Elevated hepcidin is part of a complex relation that links mortality with iron homeostasis and anemia in men and women with HIV infection. *The Journal of Nutrition: Nutrition and Disease*. 2015; 1 – 8

32. Alexaki A dan Wigdahl. HIV – 1 Infection of bone marrow hematopoietic progenitor cells and their role in trafficking and viral dissemination. *PLoS Pathogens* volume 4; 2008: 1 – 9
33. Zarychanski, R., Houston, DS. Anemia of chronic disease. A harmful or beneficial response. *CMAJ*. 2008: 179 (4), 333 – 337.
34. Wedayani AAAN, Sholikhah EN, Kristin E, Triyono EA. Risk of zidovudine-induced anemia on human immunodeficiency virus (HIV) infection patients with different CD4 cell counts. *J Med Sei*, volume 49, No1. 2017: 23 – 30
35. Bozzi A, Brisdelli F, D'Alessandro AM, D'Andrea G, Lizzi AR, Rinaldi AC *et al*. Effects AZT on cellular iron homeostasis. *Biometals*. 2004 17 : 443 – 450
36. Kementerian Kesehatan RI. Peraturan Menteri Kesehatan Republik Indonesia nomor 87 tahun 2014 tentang pedoman pengobatan antiretroviral. 2014. Jakarta : Kementerian Kesehatan
37. Saif MW. HIV-associated autoimmune hemolytic anemia: an update. *AIDS patients care and STDs* volume 15, 2001 217 – 24
38. Takuva S, Maskew M, Brennan AT, Sanne I, Macphail AP, Fox MP. Anemia among HIV-infected patients initiating antiretroviral therapy in South Africa: improvement in hemoglobin regardless of degree of immunosuppression and the initiating ART regimen. *Journal of Tropical Medicine* 2013: 1 – 6
39. Ferri RS, Adinlfi A, Orsi AJ, Sterken DJ, Keruly JC, Davis S *et al*. Treatment of anemia in patients with HIV infection – part 2: guidelines for management of anemia. *Journal of the Association of Nurses in AIDS Care*. 2002, 50 – 59
40. Hillman, R. S. Anemia. In A. S. Fauci, J. B. Martin, E. Braunwald, D. L. Kasper, K. J. Isselbacher, S. L. Hauser, J. D. Wilson, & D. L. Longo (Eds.), *Harrison's principles of internal medicine ed 20th*. New York: McGraw-Hill. 2018 pp. 334 – 339
41. Jelkmann, W. Erythropoietin: structure, control of production, and function. *Physiological Reviews*, 1992, 72, 449 – 489.

42. Fandrey J. Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. *Am J Physiol Regul Integr Comput Physiol* 2004;286:R977–88.
43. Marsden JT. Erythropoietin—measurement and clinical applications. *Ann Clin Biochem* 2006;43:97–104.
44. Munugalavadla V, Kapur R. Role of c-kit and erythropoietin receptor in erythropoiesis. *Crit Rev Oncol Hematol* 2005;54:63–75.
45. Arcasoy MO, Jiang X. Co-operative signalling mechanisms required for erythroid precursor expansion in response to erythropoietin and stem cell factor. *Br J Haematol* 2005;130:121–9.
46. Wilen CB, Tilton JC, Doms RW. HIV: cell binding and entry. *Cold Spring Harbor Perspectives in Medicine*. 2012: 1 – 13
47. Doitch G dan Greene WC. Dissecting how CD4 T cells are lost during HIV infection. *Cell Host & Microbe* 19 . 2016: 280 – 91
48. Phe T, Thai S, Veng C, Sok S, Lynen L, Griensven JV. Risk factors of treatment – limiting anemia after substitution of zidovudine for stavudine in HIV-infected adult patients on antiretroviral treatment. *PLOS one* Volume 8 issue 3. 2013: 060206
49. Wibawa KR, Merati TP, Somia A, Utama S. Faktor – faktor yang berhubungan dengan kejadian makrositosis pada pasien HIV/AIDS yang mendapat terapi zidovudine di Rumah Sakit Sanglah Denpasar. *J Peny Dalam*, Volume 11. 2010 : 33 – 40
50. Rougement M, Ngang PN, Stoll B, Delhumeau C, Hill A, Ciaffi L. *et al.* Safety of zidovudine dose reduction in treatment-naïve HIV infected patients: a randomized controlled study. *HIV Medicine*. 2016: 206 – 215
51. Parrish DD, Blevins M, Megazzini KM, Shepherd BE, Mohammed MY, Wester CW *et al.* Haemoglobin recovery among HIV – 1 infected patients on zidovudine-based antiretroviral therapy and other regimens in North – Central Nigeria. *International Journal of STD & AIDS* Vol 25. 2014 ; 5: 355 – 359

52. Dash KR, Meher LK, Hui PK, Behera SK, Nayak SN. High incidence of zidovudine induced anemia in HIV infected patients in Southern Odisha. *Indian J Hematol Blood Transfus.* 2015 ; 31 (2): 247 – 250
53. Ratanshi RP, Katende D, Levin J, Wakeham K, Heiner G, Kamali A *et al.* Development of severe anemia and changes in hemoglobin in a cohort of HIV-infected Ugandan adults receiving zidovudine, stavudine, and tenofovir containing antiretroviral regimens. *Journal of the International Association of Providers of AIDS Care.* 2014: 1 – 8
54. Tambunan AL. Hubungan antara kejadian anemia dengan kadar CD4 pada pasien HIV/AIDS yang mendapat terapi ARV dengan rejimen yang mengandung zidovudin. 2015, <https://repositori.usu.ac.id/handle/123456789/41770?show=full> diakses tanggal 15 November 2021
55. Sholikhah EN, Wedayani AAAN, Kristin E, Triyono EA. Risk of zidovudine-induced anemia on human immunodeficiency virus (HIV) infection patients with different CD4 cell counts. *J Med Sci, Volume 49.* 2017: 23 – 30
56. Huffam SE, Srasuebku P, Zhou J, Calmy A, Saphonn V, Kaldor JM *et al.* Prior antiretroviral therapy experience protects against zidovudine-related anemia. *HIV Medicine.* 2017;8:465 – 471
57. Gogu SR, Malter JS, Agrawal KC. Zidovudine – induced blockade of the expression and function of the erythropoietin receptor. *Biochemical Pharmacology, Vol 44, No 6.* 1992: 1009 – 1012
58. Nurhanisa SZ. Hubungan jumlah CD4 dengan kadar hemoglobin pada penderita HIV yang mendapat AZT. 2019, <http://repository.unissula.ac.id/id/eprint/14431> diakses tanggal 15 November 2021